Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development.
Emerging clinical evidence indicates that selective CDK9 inhibition may provide clinical benefits in the management of certain cancers.
APA
Liu Y, Xu Z, et al. (2024). Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development.. Bioorganic & medicinal chemistry letters, 112, 129941. https://doi.org/10.1016/j.bmcl.2024.129941
MLA
Liu Y, et al.. "Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development.." Bioorganic & medicinal chemistry letters, vol. 112, 2024, pp. 129941.
PMID
39222890
Abstract
Emerging clinical evidence indicates that selective CDK9 inhibition may provide clinical benefits in the management of certain cancers. Many CDK9 selective inhibitors have entered clinical developments, and are being investigated. No clear winner has emerged because of unforeseen toxicity often observed in clinic with these agents. Therefore, a novel agent with differentiated profiles is still desirable. Herein, we report our design, syntheses of a novel azaindole series of selective CDK9 inhibitors. SAR studies led to a preclinical candidate YK-2168. YK2168 exhibited improved CDK9 selectivity over AZD4573 and BAY1251152; also showed differentiated intravenous PK profile and remarkable solid tumor efficacy in a mouse gastric cancer SNU16 CDX model in preclinical studies. YK-2168 is currently in clinical development in China (CTR20212900).
MeSH Terms
Cyclin-Dependent Kinase 9; Animals; Humans; Structure-Activity Relationship; Mice; Protein Kinase Inhibitors; Molecular Structure; Antineoplastic Agents; Drug Discovery; Dose-Response Relationship, Drug; Cell Line, Tumor; Drug Screening Assays, Antitumor; Cell Proliferation
같은 제1저자의 인용 많은 논문 (5)
- Breast Morphological Comparison Between Anatomic and Round Implant Augmentation: A Prospective Study.
- Latent transforming growth factor beta binding protein 1 (LTBP1): roles as a multifunctional extracellular matrix regulator in human disease - from molecular mechanisms to clinical translation prospects.
- Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG).
- Single-cell and spatial transcriptome analysis of breast cancer tumor-associated fibroblast heterogeneity and its mediated remodeling of the tumor microenvironment.
- Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications.